• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
LI Xiaoshi, WU Xunxun, ZHENG Zuguo, YANG Hua, LI Ping. Advances of long noncoding RNAs in myocardial fibrosis[J]. Journal of China Pharmaceutical University, 2020, 51(6): 646-654. DOI: 10.11665/j.issn.1000-5048.20200602
Citation: LI Xiaoshi, WU Xunxun, ZHENG Zuguo, YANG Hua, LI Ping. Advances of long noncoding RNAs in myocardial fibrosis[J]. Journal of China Pharmaceutical University, 2020, 51(6): 646-654. DOI: 10.11665/j.issn.1000-5048.20200602
shu

Advances of long noncoding RNAs in myocardial fibrosis

More Information
  • Received Date: February 29, 2020
  • Revised Date: September 24, 2020
    Graphical Abstract
    • Abstract
  • Accumulating studies have recently shown that long noncoding RNAs (lncRNAs) are involved in the initiation and progression of myocardial fibrosis,a common histological characteristic of heart conditions and prominent global health issues. LncRNAs are prominently served as regulatory molecules via interaction with DNA,RNA and proteins in transcriptional and post-transcriptional processes. They can change morphological structure and biochemical metabolism of cardiac cells and regulate homeostasis of the cardiac extracellular matrix. Therefore,lncRNAs show great potential as diagnostic and prognostic biomarkers and therapeutic targets for anti-fibrotic treatment.
    • FullText(HTML)
    • References (59)
  • [1]
    . J Clin Invest，2007，117（3）：568?575.
    [2]
    Travers JG，Kamal FA，Robbins J，et al. Cardiac fibrosis：the fibroblast awakens［J］. Circ Res，2016，118（6）：1021?1040.
    [3]
    Gy?ngy?si M，Winkler J，Ramos I，et al. Myocardial fibrosis：biomedical research from bench to bedside［J］. Eur J Heart Fail，2017，19（2）：177?191.
    [4]
    Wang K，Liu F，Zhou LY，et al. The long noncoding RNA CHRF regulates cardiac hypertrophy by targeting miR-489［J］. Circ Res，2014，114（9）：1377?1388.
    [5]
    Wu H，Yang L，Chen LL. The diversity of long noncoding RNAs and their generation［J］. Trends Genet，2017，33（8）：540?552.
    [6]
    Yu DM，Guo W，Lei W，et al. Advances of lncRNA in immune cells and autoimmune diseases［J］. J China Pharm Univ （中国药科大学学报），2017，48（3）：371?376．
    [7]
    Yao RW，Wang Y，Chen LL. Cellular functions of long noncoding RNAs［J］. Nat Cell Biol，2019，21（5）：542?551.
    [8]
    Ruiz-Orera J，Messeguer X，Subirana JA，et al. Long non-coding RNAs as a source of new peptides［J］. Elife，2014，3：e03523.
    [9]
    Chen YG，Satpathy AT，Chang HY. Gene regulation in the immune system by long noncoding RNAs［J］. Nat Immunol，2017，18（9）：962?972.
    [10]
    Martianov I，Ramadass A，Serra Barros A，et al. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript［J］. Nature，2007，445（7128）：666?670.
    [11]
    Kopp F，Mendell JT. Functional classification and experimental dissection of long noncoding RNAs［J］. Cell，2018，172（3）：393?407.
    [12]
    Engreitz JM，Haines JE，Perez EM，et al. Local regulation of gene expression by lncRNA promoters，transcription and splicing［J］. Nature，2016，539（7629）：452?455.
    [13]
    Cao F，Li Z，Ding WM，et al. LncRNA PVT1 regulates atrial fibrosis via miR-128-3p-SP1-TGF-β1-Smad axis in atrial fibrillation［J］. Mol Med，2019，25（1）：7.
    [14]
    Jin K，Wang S，Zhang Y，et al. Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis［J］. Cell Mol Life Sci，2019，76（21）：4275?4289.
    [15]
    Huang Y. The novel regulatory role of lncRNA‐miRNA‐mRNA axis in cardiovascular diseases［J］. J Cell Mol Med，2018，22（12）：5768?5775.
    [16]
    Morgoulis D，Berenstein P，Cazacu S，et al. sPIF promotes myoblast differentiation and utrophin expression while inhibiting fibrosis in Duchenne muscular dystrophy via the H19/miR-675/let-7 and miR-21 pathways［J］. Cell Death Dis，2019，10（2）：82.
    [17]
    Li D，Zhang CL，Li J，et al. Long non-coding RNA MALAT1 promotes cardiac remodeling in hypertensive rats by inhibiting the transcription of MyoD［J］. Aging，2019，11（20）：8792?8809.
    [18]
    Li Z，Liu Y，Guo X，et al. Long noncoding RNA myocardial infarction-associated transcript is associated with the microRNA-150-5p/P300 pathway in cardiac hypertrophy［J］. Int J Mol Med，2018，42（3）：1265?1272.
    [19]
    Qu X，Du Y，Shu Y，et al. MIAT is a pro-fibrotic long non-coding RNA governing cardiac fibrosis in post-infarct myocardium［J］. Sci Rep，2017，7：42657.
    [20]
    Huang S，Zhang L，Song J，et al. Long noncoding RNA MALAT1 mediates cardiac fibrosis in experimental postinfarct myocardium mice model［J］. J Cell Physiol，2019，234（3）：2997?3006.
    [21]
    Yuan JH，Liu XN，Wang TT，et al. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1［J］. Nat Cell Biol，2017，19（7）：820?832.
    [22]
    Guo M，Liu TY，Zhang SJ，et al. RASSF1-AS1，an antisense lncRNA of RASSF1A，inhibits the translation of RASSF1A to exacerbate cardiac fibrosis in mice［J］. Cell Biol Int，2019，43（10）：1163?1173.
    [23]
    Hao K，Lei W，Wu H，et al. LncRNA-Safe contributes to cardiac fibrosis through Safe-Sfrp2-HuR complex in mouse myocardial infarction［J］. Theranostics，2019，9（24）：7282?7297.
    [24]
    Yu Y，Nangia-Makker P，Farhana L，et al. A novel mechanism of lncRNA and miRNA interaction：CCAT2 regulates miR-145 expression by suppressing its maturation process in colon cancer cells［J］. Mol Cancer，2017，16（1）：155.
    [25]
    Hosseini E，Bagheri-Hosseinabadi Z，de Toma I，et al. The importance of long non-coding RNAs in neuropsychiatric disorders［J］. Mol Aspects Med，2019，70：127?140.
    [26]
    Piccoli MT，Gupta SK，Viereck J，et al. Inhibition of the cardiac fibroblast-enriched lncRNA Meg3 prevents cardiac fibrosis and diastolic dysfunction［J］. Circ Res，2017，121（5）：575?583.
    [27]
    Choong OK，Chen CY，Zhang J，et al. Hypoxia-induced H19/YB-1 cascade modulates cardiac remodeling after infarction［J］. Theranostics，2019，9（22）：6550?6567.
    [28]
    Zheng D，Zhang Y，Hu Y，et al. Long noncoding RNA Crnde attenuates cardiac fibrosis via Smad3-Crnde negative feedback in diabetic cardiomyopathy［J］. Febs J，2019，286（9）：1645?1655.
    [29]
    Kumar A，Thomas SK，Wong KC，et al. Mechanical activation of noncoding-RNA-mediated regulation of disease-associated phenotypes in human cardiomyocytes［J］. Nat Biomed Eng，2019，3（2）：137?146.
    [30]
    Mathy NW，Chen XM. Long non-coding RNAs （lncRNAs） and their transcriptional control of inflammatory responses［J］. J Biol Chem，2017，292（30）：12375?12382.
    [31]
    Dykes IM，Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA［J］. Genomics Proteomics Bioinformatics，2017，15（3）：177?186.
    [32]
    Willingham AT，Orth AP，Batalov S，et al. A strategy for probing the function of noncoding RNAs finds a repressor of NFAT［J］. Science，2005，309（5740）：1570?1573.
    [33]
    Rudi M，Isabelle P，Brian J，et al. The long noncoding RNA Wisper controls cardiac fibrosis and remodeling［J］ . Sci Transl Med，2017，9（395）：eaai9118．
    [34]
    Kong P，Christia P，Frangogiannis NG. The pathogenesis of cardiac fibrosis［J］. Cell Mol Life Sci，2014，71（4）：549?574.
    [35]
    Feng Y，Xu W，Zhang W，et al. LncRNA DCRF regulates cardiomyocyte autophagy by targeting miR-551b-5p in diabetic cardiomyopathy［J］. Theranostics，2019，9（15）：4558?4566.
    [36]
    Liu Y，Wang T，Zhang M，et al. Down-regulation of myocardial infarction associated transcript 1 improves myocardial ischemia-reperfusion injury in aged diabetic rats by inhibition of activation of NF-κB signaling pathway［J］. Chem Biol Interact，2019，300：111?122.
    [37]
    Zhang BF，Jiang H，Chen J，et al. LncRNA H19 ameliorates myocardial infarction-induced myocardial injury and maladaptive cardiac remodelling by regulating KDM3A［J］. J Cell Mol Med，2020，24（1）：1099?115.
    [38]
    Congrains A，Kamide K，Ohishi M，et al. ANRIL：molecular mechanisms and implications in human health［J］. Int J Mol Sci，2013，14（1）：1278?1292.
    [39]
    Prabhu SD，Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction：from inflammation to fibrosis［J］. Circ Res，2016，119（1）：91?112.
    [40]
    Hulshoff MS，Xu X，Krenning G，et al. Epigenetic regulation of endothelial-to-mesenchymal transition in chronic heart disease：histone modifications，DNA methylation，and noncoding RNAs［J］. Arterioscler Thromb Vasc Biol，2018，38（9）：1986?1996.
    [41]
    Tao H，Zhang JG，Qin RH，et al. LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway［J］. Toxicology，2017，386：11?18.
    [42]
    Yang Z，Jiang S，Shang J，et al. LncRNA：Shedding light on mechanisms and opportunities in fibrosis and aging［J］. Ageing Res Rev，2019，52：17?31.
    [43]
    She Q，Shi P，Xu SS，et al. DNMT1 methylation of LncRNA GAS5 leads to cardiac fibroblast pyroptosis via affecting NLRP3 axis［J］. Inflammation，2020，43（3）：1065?1076.
    [44]
    Man SM，Karki R，Kanneganti TD. Molecular mechanisms and functions of pyroptosis，inflammatory caspases and inflammasomes in infectious diseases［J］. Immunol Rev，2017，277（1）：61?75.
    [45]
    Yang F，Qin Y，Lv J，et al. Silencing long non-coding RNA Kcnq1ot1 alleviates pyroptosis and fibrosis in diabetic cardiomyopathy［J］. Cell Death Dis，2018，9（10）：1000.
    [46]
    Kenneweg F，Bang C，Xiao K，et al. Long noncoding RNA-enriched vesicles secreted by hypoxic cardiomyocytes drive cardiac fibrosis［J］. Mol Ther Nucleic Acids，2019，18：363?374.
    [47]
    Lan TH，Huang XQ，Tan HM. Vascular fibrosis in atherosclerosis［J］. Cardiovasc Pathol，2013，22（5）：401?407.
    [48]
    Huang ZP，Ding Y，Chen J，et al. Long non-coding RNAs link extracellular matrix gene expression to ischemic cardiomyopathy［J］. Cardiovasc Res，2016，112（2）：543?554.
    [49]
    Huang ZW，Tian LH，Yang B，et al. Long noncoding RNA H19 acts as a competing endogenous RNA to mediate CTGF expression by sponging miR-455 in cardiac fibrosis［J］. DNA Cell Biol，2017，36（9）：759?766.
    [50]
    Zhuang Y，Li T，Zhuang Y，et al. Involvement of lncR-30245 in myocardial infarction-induced cardiac fibrosis through peroxisome proliferator-activated receptor-γ-mediated connective tissue growth factor signalling pathway［J］. Can J Cardiol，2019，35（4）：480?489.
    [51]
    Gong L，Zhu L，Yang T. Fendrr involves in the pathogenesis of cardiac fibrosis via regulating miR-106b/SMAD3 axis［J］. Biochem Biophys Res Commun，2020，524（1）：169?177.
    [52]
    Ouyang F，Liu X，Liu G，et al. Long non-coding RNA RNF7 promotes the cardiac fibrosis in rat model via miR-543/THBS1 axis and TGFβ1 activation［J］. Aging （Albany NY），2020，12（1）：996?1010.
    [53]
    Lo Sardo V，Chubukov P，Ferguson W，et al. Unveiling the role of the most impactful cardiovascular risk locus through haplotype editing［J］. Cell，2018，175（7）：1796?1810.
    [54]
    Liu L，Zhang QW，Nong C，et al. Research progress of lncRNA regulating signal transduction pathway in liver diseases［A］. J China Pharm Univ （中国药科大学学报），2020，51（3）：277?286．
    [55]
    Lucas T，Bonauer A，Dimmeler S. RNA therapeutics in cardiovascular disease［J］. Circ Res，2018，123（2）：205?220.
    [56]
    Gezer U，?zgür E，Cetinkaya M，et al. Long non-coding RNAs with low expression levels in cells are enriched in secreted exosomes［J］. Cell Biol Int，2014，38（9）：1076?1079.
    [57]
    Zhou J，Zhou Y，Wang CX. LncRNA-MIAT regulates fibrosis in hypertrophic cardiomyopathy （HCM） by mediating the expression of miR-29a-3p［J］. J Cell Biochem，2019，120（5）：7265?7275.
    [58]
    Puthanveetil P，Gutschner T，Lorenzen J. MALAT1：a therapeutic candidate for a broad spectrum of vascular and cardiorenal complications［J］. Hypertens Res，2020，43（5）：372?379.
    [59]
    Matboli M，Habib EK，Hussein Mohamed R，et al. Pentoxifylline alleviated cardiac injury via modulating the cardiac expression of lncRNA-00654-miR-133a-SOX5 mRNA in the rat model of ischemia-reperfusion［J］. Biomed Pharmacother，2020，124：109842.
    • Related Articles

  • Related Articles

    [1]ZHOU Xinyuan, LIU Nan, ZHANG Pan, HUO Meirong. Advances in research on therapeutic strategies of targeting pancreatic cancer stroma[J]. Journal of China Pharmaceutical University, 2021, 52(6): 653-662. DOI: 10.11665/j.issn.1000-5048.20210602
    [2]YAN Pei, YE Lianbao, CHEN Weiqiang. Progress in therapeutic targets and development of drugs against chronic obstructive pulmonary disease[J]. Journal of China Pharmaceutical University, 2021, 52(2): 144-155. DOI: 10.11665/j.issn.1000-5048.20210202
    [3]XIA Ying, GUO Hongli, HU Yahui, CHEN Feng. Therapeutic drug monitoring for monoclonal antibody：progress in the application of LC-MS/MS technique[J]. Journal of China Pharmaceutical University, 2021, 52(1): 122-128. DOI: 10.11665/j.issn.1000-5048.20210117
    [4]WANG Xue, YANG Tingting, JIANG Zhenzhou, ZHANG Luyong. Tight junctions-associated proteins:a novel therapeutic target for cholestatic liver injury[J]. Journal of China Pharmaceutical University, 2019, 50(2): 143-151. DOI: 10.11665/j.issn.1000-5048.20190203
    [5]LI Long, KOU Junping. Advances in the research of therapeutic targets and the development of new drugs against arterial thrombosis[J]. Journal of China Pharmaceutical University, 2017, 48(3): 251-258. DOI: 10.11665/j.issn.1000-5048.20170301
    [6]ZHAO Yuekui, TANG Shanshan, ZHANG Yanfeng, ZONG Li, JIN Liang. Engineered mesenchymal stem cells as targeting therapeutic carriers in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(2): 134-139. DOI: 10.11665/j.issn.1000-5048.20160202
    [7]LI Chen, YUAN Linhua, MA Xueqin, LIU Xiaoquan, XI Tao. Variation of cardiovascular risk biomarkers in type 2 diabetes mellitus[J]. Journal of China Pharmaceutical University, 2013, 44(3): 257-262. DOI: 10.11665/j.issn.1000-5048.20130314
    [8]SONG Jiemei, WEN Xiaoan, SUN Hongbin. Progress in pathogenesis and therapeutic drugs of pulmonary arterial hypertension[J]. Journal of China Pharmaceutical University, 2013, 44(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20130101
    [9]Application of pharmacometrics in drug development and therapeutic drug monitoring[J]. Journal of China Pharmaceutical University, 2010, 41(1): 91-96.
    [10]Research Advances in the Targeting of Epidermal Growth Factor Receptor[J]. Journal of China Pharmaceutical University, 2004, (3): 91-94.

  • Cited by

    Periodical cited type(1)

    1. 周霞辉，罗晓欣，周曼丽，俞赟丰，赵彦禛，张宜帆，简维雄. 冠状动脉粥样硬化性心脏病血瘀证表观遗传学研究进展. 中国中医药信息杂志. 2022(06): 148-152 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML
    Article views (281) PDF downloads (685) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：304019

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return